drugset / Trial / NCT01525836

Summary

The project was undertaking by Qilu Hospital of Shandong University and other 13 well-known hospitals in China. In order to report the efficacy and safety of Recombinant Human thrombopoietin combining with Rituximab for the treatment of adults with refractory immune thrombocytopenia (ITP), compared to conventional Rituximab therapy.

Timeline

Start
2011-05
Primary completion
2013-12
Completion
2014-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Rituximab Monoclonal antibody 100 mg Intravenous
Subject recombinant human thrombopoietin Protein / enzyme biologic 300 iu/kg Subcutaneous